Mark Gottlieb
@Altium Capital Management Lp
Latest period2024 - Q3ReportedManaged Assets$339.708MTotal holdings77
Assets growth rate-99.86%Assets growth rate (2-Q avg)-51.42%Continuous growth in asset value0 quarters
Portfolio positions
This chart displays the top 10 holdings in Altium Capital Management Lp's 2024 - Q3 portfolio, based on their 13F SEC filing, out of a total of 77 positions.
Assets under management
The assets under management (AUM) of Altium Capital Management Lp over the past 10 years (40 quarters) show continuous growth in total asset value over the last 0 quarters. As of the latest 13F SEC filing for 2024 - Q3, they manage 339.708M in assets, with a quarterly growth rate of -99.86% and a 2-quarter average growth rate of -51.42%. The portfolio is managed by Mark Gottlieb, and others.
Portfolio holdings
Investment | Portfolio % | Reported Value | Recent Activity |
---|---|---|---|
LRMRLarimar Therapeutics Inc
| 1.72% | $5.823M 889,000 shares@ $6.55 avg price | |
EOLSEvolus Inc
| 1.7% | $5.751M 355,000 shares@ $16.2 avg price | New Position |
ESTAEstablishment Labs Hldgs Inc
| 1.67% | $5.668M 131,000 shares@ $43.27 avg price | New Position |
RXSTRxsight Inc
| 1.63% | $5.536M 112,000 shares@ $49.43 avg price | New Position |
AXSMAxsome Therapeutics Inc
| 1.54% | $5.212M 58,000 shares@ $89.87 avg price | Increased 16% |
SKYESkye Bioscience Inc
| 1.52% | $5.142M 1.315M shares@ $3.92 avg price | Decreased -2.58% |
XTNTXtant Med Hldgs Inc
| 1.48% | $5.013M 7.415M shares@ $0.68 avg price | |
CAPRCapricor Therapeutics Inc
| 1.28% | $4.335M 285,000 shares@ $15.21 avg price | New Position |
LUNGPulmonx Corp
| 1.23% | $4.145M 500,000 shares@ $8.29 avg price | New Position |
CRBPCorbus Pharmaceuticals Hldgs
| 1.19% | $4.023M 195,000 shares@ $20.63 avg price | New Position |